Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$10.93
$4.51
$20.20
$236.61M0.4162,237 shs171,500 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-8.0%
$0.01
$0.01
$0.02
$1.19M-0.92432,762 shs764,979 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.13
+5.6%
$0.73
$0.28
$2.45
$386.80M1.136.86 million shs5.27 million shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.01
+233.3%
$0.03
$0.00
$6.93
$241K1.318.06 million shs54,905 shs
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$7.95
+3.2%
$6.71
$5.04
$16.74
$1.20B-1.011.29 million shs2.57 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00%0.00%0.00%0.00%0.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-8.00%-8.00%-8.00%-3.16%-8.00%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+5.61%+24.18%+61.18%+120.79%-30.67%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
+233.33%-64.14%-64.14%-62.50%-99.84%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+3.25%+14.06%+9.96%+40.71%+42.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.6354 of 5 stars
0.03.00.04.80.00.00.0
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.7867 of 5 stars
3.23.00.00.02.32.50.6
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.3675 of 5 stars
3.15.00.04.31.12.50.6
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
4.4466 of 5 stars
3.51.00.04.82.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67224.48% Upside
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3336,937.04% Upside
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.92
Moderate Buy$20.50157.86% Upside

Current Analyst Ratings Breakdown

Latest SYRS, WVE, EVFM, LXRX, and ADRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/23/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
6/11/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
4/29/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$17.26M0.00N/AN/A$4.07 per share0.00
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.21M13.09N/AN/A$0.40 per share2.83
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.63N/AN/A$0.79 per share0.01
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$108.30M11.42N/AN/A$1.37 per share5.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/14/2025 (Estimated)

Latest SYRS, WVE, EVFM, LXRX, and ADRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/8/2025Q1 2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/A
8.91
8.91
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
2.95
2.95

Institutional Ownership

CompanyInstitutional Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
49.93%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
15216.21 millionN/AOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240155.56 million118.26 millionOptionable

Recent News About These Companies

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50
Wave Life Sciences: Speculative, But Promising
Wave Life Sciences Ltd. (WVE) - Yahoo Finance
Where WAVE Life Sciences Stands With Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aduro Biotech stock logo

Aduro Biotech NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0092 0.00 (-8.00%)
As of 07/10/2025 03:59 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.13 +0.06 (+5.61%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.13 0.00 (0.00%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0090 +0.01 (+233.33%)
As of 07/10/2025 03:58 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$7.95 +0.25 (+3.25%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$8.17 +0.22 (+2.77%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.